News Focus
News Focus
Replies to #99721 on Biotech Values
icon url

rkrw

07/26/10 1:28 PM

#99723 RE: bladerunner1717 #99721

I don't think so.

As you can see Myeloma patients go through a lot of regimens. Onyx results don't change that.



icon url

rkrw

07/26/10 2:09 PM

#99725 RE: bladerunner1717 #99721

I would add the MM space is very crowded but it was already crowded before.

Abbott/Facet antibody looks very promising.
This Onxy compound looked good.
There's a next generation Revlimid that should be a lock.

Beyond that I'm not sure there's much to get overly excited about in MM and nothing in small cap biotech that I'm aware of. imo.